Multiple sclerosis and exposure to organic solvents, investigated by genetic polymorphisms of the GSTM1 and CYP2D6 enzyme systems

Neurological Sciences

Volumn 24, Issue 4, 2003, Pages 248-251

  Landtblom, A M ^a   Wastenson, M ^a   Ahmadi, A ^a   Soderkvist P ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

Author keywords

CYP2D6; Exposure; Genetic polymorphism; GSTM1; HLA Dw2; Multiple sclerosis; Organic solvents

Indexed keywords

CELL DNA; CYTOCHROME P450 2D6; GLUTATHIONE TRANSFERASE; ORGANIC SOLVENT;

ADULT; AGED; ARTICLE; BRAIN DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; ENVIRONMENTAL EXPOSURE; ENZYME POLYMORPHISM; FEMALE; GENETIC PREDISPOSITION; GENOTYPE; HUMAN; LEUKOCYTE; MALE; MULTIPLE SCLEROSIS; POLYMERASE CHAIN REACTION;

ADULT; AGED; CONFIDENCE INTERVALS; CYTOCHROME P-450 CYP2D6; DNA; FEMALE; GENOTYPE; GLUTATHIONE TRANSFERASE; HUMANS; INHALATION EXPOSURE; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; ODDS RATIO; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; SOLVENTS;

EID: 0344308269     PISSN: 15901874     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10072-003-0148-5     Document Type: Article

References (32)

1. Matthews WB (1991) Course and prognosis. In: Matthews WB, Compston A, Allen I, Martyn CN (eds) McAlpine's multiple sclerosis. Churchill Livingstone, Melbourne New York, pp 139-169
2. Compston A (1997) Genetic epidemiology of multiple sclerosis. J Neurol Neurosurg Psychiatry 62:553-561
3. Oksenberg JR, Baranzini SE, Barcellos LF, Hauser SL (2001) Multiple sclerosis. Genomic rewards. J Neuroimmunol 113:171-184
4. Barcellos LF, Oksenberg JR, Green AJ, Bucher P, Rimmler JB, Schmidt S, Garcia ME, Lincoln RR, Pericak-Vance MA, Haines JL, Hauser SI (2002) Genetic basis for clinical expression in multiple sclerosis. Brain 125:150-158
5. Riise T, Wolfson C (eds) (1997) The epidemiologic study of exogenous factors in the etiology of multiple sclerosis. Neurology 49[Suppl 2]
6. Allen M, Sandberg-Wollheim M, Sjogren K, Erlich HA, Petterson U, Gyllensten U (1994) Association of susceptibility to multiple sclerosis in Sweden with HLA class II DRB1 and DQB1 alleles. Hum Immunol 39:41-48
7. Spencer PS, Schaumburg HH (eds) (1980) Experimental and clinical neurotoxicology.Williams Wilkins, Baltimore
8. Axelson O, Hogstedt C (1994) The health effects of solvents. In: Zenz C, Dickerson OB, Horvath EP Jr (eds) Occupational medicine. Mosby, St. Louis, pp 764-778
9. Axelson O (1995) Neurobehavioural effects. In: McDonald C (ed) Epidemiology of work-related diseases. BMJ, London, pp 165-184
10. Moszcynski P (1981) Organic solvents and T-lymphocytes. Lancet 21:438
11. Juntunen J, Taskinen E, Luisto M, Iivanainen M, Nurminen M (1982) Cerebrospinal fluid cells and proteins in patients occupationally exposed to organic solvents. J Neurol Sci 54:413-425
12. Landtblom AM, Flodin U, Karlsson M, Pålhagen S, Axelson O, Söderfeldt B (1993) Multiple sclerosis and exposure to solvents, ionizing radiation and animals. Scand J Work Environ Health 19:399-404
13. Flodin U, Söderfeldt B, Noorlind-Brage H, Fredriksson M, Axelson O (1988) Multiple sclerosis, solvents and pets. Arch Neurol 45:620-623
14. Grönning M, Albrektsson G, Kvåle G, Moen B, Aarli JA, Nyland H (1993) Organic solvents and multiple sclerosis: a case-control study. Acta Neurol Scand 88:247-250
15. Casetta I, Granieri E, Malagu S, Tola MR, Paolino E, Caniatti LM (1994 ) Environmental risk factors and multiple sclerosis: a community-based case-control study in the province of Ferrara, Italy. Neuroepidemiology 13:120-128
16. Amaducci L, Arfaioli C, Inzitari D, Marchi M (1982) Multiple sclerosis among shoe and leather workers: an epidemiological survey in Florence. Acta Neurol Scand 65:94-103
17. Landtblom AM (1997) Exposure to organic solvents and MS. Neurology 49[Suppl 2]:S70-S74
18. Reis J, Dietemann JL, Warter JM, Poser CM (2001) A case of multiple sclerosis triggered by organic solvents. Neurol Sci 22:155-158
19. Landtblom AM, Thuomas KÅ, Sjöqvist L, Flodin U, Nyland H, Söderfeldt B (2003) Hypointensity in T2-weighted images of basal ganglia in solvent-exposed MS patients: clinical, MRI and CSF characteristics. Neurol Sci 24(1):2-9
20. Landtblom AM, Flodin U, Söderfeldt B, Wolfson C, Axelson O (1996) Organic solvents and multiple sclerosis: a synthesis of the current evidence. Epidemiology 7:429-433
21. Ketterer B, Coles B, Meyer DJ (1983) The role of glutathione in detoxification. Environ Health Perspect 49:55-69
22. Zhong S, Wyllie AH, Barnes D, Wolf CR, Spurr NK (1993) Relationship between the GSTM1 genetic polymorphism and susceptibility to bladder, breast and colon cancer. Carcinogenesis 14(9):1821-1824
23. Ahmadi A, Fredrikson M, Jerregård H, Åkerbäck A, Fall PA, Rannug A, Axelson O, Söderkvist P (2000) GSTM1 and mEPHX polymorphisms in Parkinson's disease and age of onset. Biochem Biophys Res Commun 269:676-680
24. Brockmöller J, Kerb R, Drakoulis N, Staffeldt B, Roots I (1994) Glutathione S-transferase M1 and its variants A and B as host factors of bladder cancer susceptibility: a case-control study. Cancer Res 54:4103-4111
25. Hirvonen A, Husgafvel-Pursainen K, Anttila S, Vaino H (1993) The GSTM1 null genotype as a potential risk modifier for squamoouos cell carcinoma of the lung. Carcinogenesis 14(7):1479-1481
26. Söderkvist P, Ahmadi A, Åkerback A, Axelson O, Flodin U (1996) Glutathione S-transferase M1 null genotype as a risk modifier for solvent-induced chronic toxic encephalopathy. Scand J Work Environ Health 22(5):360-363
27. Smith ADC, Gough AC, Nigel Leigh P, Summers BA, Harding AE, Maranganore DM (1992) Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease. Lancet 339:1375-1377
28. Benitez J, Ladero JM, Jimenez-Jimenez FJ, Martinez C, Puerto AM, Valdivielso MJ (1990) Oxidative polymorphism of debrisoquine in Parkinson's disease. J Neurol Neurosurg Psychiatry 53:289-292
29. Armstrong M, Daly AK, Cholerton S, Batesman DN, Idle JR (1992) Mutant debrisoquine hydroxylation genes in Parkinson's disease. Lancet 399:1017-1018
30. Poser C, Paty D, Scheinberg L, McDonald WI, Davies FA, Ebers GC (1983) New diagnostic criteria for multiple sclerosis. Ann Neurol 13:227-231
31. Fryer AA, Zhao L, Alldersea J, Pearson WR, Strange R (1993) Use of site-directed mutagenesis of allele-specific PCR primers to identify the GSTM1 A, GSTM1 B, GSTM1 A, B and GSTM1 null polymorphisms at the glutathione S-transferase, GSTM1 locus. Biochemistry 295:313-315
32. Fryer AA, Zhao L, Alldersea J, Pearson WR, Strange R (1994) Epi Info version 6.02. Centers for Disease Control and Prevention, Atlanta